Hims, an online telehealth platform, offers consultations and prescription medications for ED and other conditions. But is it the best option for you in 2024? In this Hims ED medication review we ...

Since labeling Hims & Hers a “generational” buy at $3.40 per share in May 2022, I have re-iterated my uber-bullish stance on HIMS stock — supported by impressive business performance from ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our P/B Growth Investor model based on the published ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $42.00. Discover the ...